OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer ...
10don MSNOpinion
China Is Building the Future
A fter a months-long trade war between China and the United States, Presidents Donald Trump and Xi Jinping are scheduled to ...
Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL:Lasme-cel in ...
Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that NBD1 ...
The MarketWatch News Department was not involved in the creation of this content.-- Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associate ...
Next & GSK Drive Rally.) Next surges on profit upgrade Next shares jumped more than 7% after the retailer raised its ...
The BancAnalysts Association of Boston Conference November 6, 2025 12:45 PM ESTCompany ParticipantsBrendan Coughlin ...
The weekday streets are quiet in the mountain town of Caramulo, the calm broken only by the growl of a sports car or the ...
The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG ...
CELEBRATION, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with ...
Amgen today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback